Details of the Drug Combination

General Information of Drug Combination (ID: DCRIRHD)

Drug Combination Name
Berberine Carvedilol
Indication
Disease Entry Status REF
Cirrhosis Due to Hepatitis B Phase 3 [1]
Component Drugs Berberine   DMC5Q8X Carvedilol   DMHTEAO
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Berberine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Telomerase reverse transcriptase (TERT) TTUJFD0 TERT_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Berberine Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
------------------------------------------------------------------------------------
Berberine Interacts with 137 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [11]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Activity [11]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Decreases Expression [12]
Protein arginine N-methyltransferase 5 (PRMT5) OTF6IGJS ANM5_HUMAN Increases Expression [6]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Activity [13]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Increases Expression [14]
Histone acetyltransferase type B catalytic subunit (HAT1) OT307KEN HAT1_HUMAN Increases Expression [6]
Lysine-specific demethylase 6B (KDM6B) OTMZVHSG KDM6B_HUMAN Increases Expression [6]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Affects Binding [15]
Lysine-specific demethylase 6A (KDM6A) OTZM3MJJ KDM6A_HUMAN Increases Expression [6]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [16]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Increases Expression [17]
Lysine-specific histone demethylase 1A (KDM1A) OT85JXS5 KDM1A_HUMAN Increases Expression [6]
Histone H2B type 1-K (H2BC12) OTQ8V0KG H2B1K_HUMAN Decreases Expression [6]
Lysine-specific demethylase 4A (KDM4A) OTDN3EGK KDM4A_HUMAN Increases Expression [6]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [18]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Expression [14]
Histone-lysine N-methyltransferase NSD2 (NSD2) OTQ6SW4R NSD2_HUMAN Decreases Expression [6]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [5]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [19]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [7]
Collagen alpha-1(II) chain (COL2A1) OT5E59C8 CO2A1_HUMAN Decreases Expression [7]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Increases Expression [7]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [19]
Histone H2A type 1-B/E (H2AC4) OTMFQ662 H2A1B_HUMAN Decreases Expression [6]
Histone H2B type 1-J (H2BC11) OTGM083T H2B1J_HUMAN Decreases Expression [6]
Cathepsin D (CTSD) OTQZ36F3 CATD_HUMAN Decreases Cleavage [17]
Procathepsin L (CTSL) OTYTUW29 CATL1_HUMAN Decreases Cleavage [17]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Increases Expression [20]
72 kDa type IV collagenase (MMP2) OT5NIWA2 MMP2_HUMAN Decreases Activity [21]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [7]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [20]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [22]
Histone H2A type 1 (H2AC11) OTN9P0BO H2A1_HUMAN Decreases Expression [6]
Histone H2B type F-M (H2BW2) OT4X4HHV H2BFM_HUMAN Decreases Expression [6]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [19]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Increases Expression [7]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Decreases Activity [14]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [22]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Increases Expression [23]
Sucrase-isomaltase, intestinal (SI) OTUP724T SUIS_HUMAN Decreases Expression [24]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Activity [5]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Decreases Expression [7]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Decreases Expression [6]
Aggrecan core protein (ACAN) OTUOCW8K PGCA_HUMAN Decreases Expression [7]
Platelet glycoprotein 4 (CD36) OT5CZWKY CD36_HUMAN Increases Expression [25]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Increases Expression [25]
Cadherin-2 (CDH2) OTH0Y56P CADH2_HUMAN Decreases Expression [7]
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Decreases Activity [26]
Histone H2B type 1-O (H2BC17) OT8ED05P H2B1O_HUMAN Decreases Expression [6]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [22]
G1/S-specific cyclin-E1 (CCNE1) OTLD7UID CCNE1_HUMAN Decreases Expression [22]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [22]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [19]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Decreases Expression [6]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [22]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [5]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Expression [7]
Sterol regulatory element-binding protein 1 (SREBF1) OTWBRPAI SRBP1_HUMAN Decreases Expression [7]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Expression [7]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [22]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [19]
Growth/differentiation factor 5 (GDF5) OTOV8S81 GDF5_HUMAN Decreases Expression [7]
Nicotinamide phosphoribosyltransferase (NAMPT) OTVJR3GL NAMPT_HUMAN Decreases Expression [16]
Collagenase 3 (MMP13) OTY8BZIE MMP13_HUMAN Increases Expression [7]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [22]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [19]
Transcription factor SOX-9 (SOX9) OTVDJFGN SOX9_HUMAN Decreases Expression [7]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Decreases Expression [7]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [20]
Cyclin-dependent kinase inhibitor 1C (CDKN1C) OTASTJ3Q CDN1C_HUMAN Increases Expression [7]
Isocitrate dehydrogenase subunit alpha, mitochondrial (IDH3A) OT5QQB5L IDH3A_HUMAN Decreases Expression [27]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Cleavage [22]
Protein arginine N-methyltransferase 2 (PRMT2) OT63JZCI ANM2_HUMAN Increases Expression [6]
Integrin alpha-1 (ITGA1) OTDITIST ITA1_HUMAN Increases Expression [7]
Histone H2B type 1-D (H2BC5) OTXDTDHN H2B1D_HUMAN Decreases Expression [6]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [28]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Decreases Expression [6]
Histone H2B type 1-C/E/F/G/I (H2BC10) OTLQH0D6 H2B1C_HUMAN Decreases Expression [6]
Histone H3.1 (H3C1) OTGBGOZW H31_HUMAN Decreases Expression [6]
Histone H3.3 (H3-3B) OT9XHQ3C H33_HUMAN Decreases Expression [6]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [22]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [22]
Collagen alpha-1(X) chain (COL10A1) OTC4G2YC COAA1_HUMAN Increases Expression [7]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [19]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [22]
Histone acetyltransferase p300 (EP300) OTL8QJDX EP300_HUMAN Increases Expression [6]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Increases Expression [17]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Increases Expression [19]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [17]
Runt-related transcription factor 2 (RUNX2) OT97RQQM RUNX2_HUMAN Increases Expression [7]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [19]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [27]
Histone-lysine N-methyltransferase SETDB1 (SETDB1) OTWVUA1B SETB1_HUMAN Increases Expression [6]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Activity [27]
Histone H3.1t (H3-4) OTY6ITYF H31T_HUMAN Decreases Expression [6]
Histone H2A type 2-A (H2AC18) OTCE5JC7 H2A2A_HUMAN Decreases Expression [6]
Histone H2A type 3 (H2AC25) OTPO62JI H2A3_HUMAN Decreases Expression [6]
Actin-histidine N-methyltransferase (SETD3) OTO5RAU2 SETD3_HUMAN Increases Expression [6]
E3 ubiquitin-protein ligase DZIP3 (DZIP3) OTOFK9KG DZIP3_HUMAN Increases Expression [6]
FUN14 domain-containing protein 1 (FUNDC1) OTA6IVKQ FUND1_HUMAN Increases Expression [17]
Thiosulfate:glutathione sulfurtransferase (TSTD1) OT5DMKFX TSTD1_HUMAN Increases Expression [6]
N-lysine methyltransferase SETD6 (SETD6) OTH5APN1 SETD6_HUMAN Increases Expression [6]
Transcription factor Sp7 (SP7) OT07ETZT SP7_HUMAN Increases Expression [7]
Histone-lysine N-methyltransferase SETD7 (SETD7) OTT49OXF SETD7_HUMAN Increases Expression [6]
Histone deacetylase 2 (HDAC2) OTUYVFKN HDAC2_HUMAN Decreases Expression [6]
CREB-binding protein (CREBBP) OTPA4QGM CBP_HUMAN Increases Expression [6]
Proteoglycan 4 (PRG4) OT34NR3N PRG4_HUMAN Decreases Expression [7]
Histone H2A type 1-C (H2AC6) OTF3YK7V H2A1C_HUMAN Decreases Expression [6]
Histone H2B type 1-H (H2BC9) OTQ9XX72 H2B1H_HUMAN Decreases Expression [6]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Decreases Expression [16]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Decreases Expression [6]
Histone H2A type 1-H (H2AC12) OTLXVB97 H2A1H_HUMAN Decreases Expression [6]
Protein arginine N-methyltransferase 6 (PRMT6) OT5V3XIN ANM6_HUMAN Increases Expression [6]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [16]
Histone-lysine N-methyltransferase SETDB2 (SETDB2) OTBVVP9Q SETB2_HUMAN Increases Expression [6]
Protein arginine N-methyltransferase 1 (PRMT1) OTN8GTXW ANM1_HUMAN Decreases Expression [6]
Histone H2B type 1-N (H2BC15) OTU39CFZ H2B1N_HUMAN Decreases Expression [6]
Histone H2A type 1-J (H2AC14) OT5Y4MMC H2A1J_HUMAN Decreases Expression [6]
Histone H2B type 1-M (H2BC14) OTSDZZZY H2B1M_HUMAN Decreases Expression [6]
Histone H2B type 1-L (H2BC13) OTIS8L6R H2B1L_HUMAN Decreases Expression [6]
Osteomodulin (OMD) OTFRELBB OMD_HUMAN Increases Expression [7]
Histone deacetylase 8 (HDAC8) OT5L4RYX HDAC8_HUMAN Decreases Expression [6]
Histone-lysine N-methyltransferase SETD2 (SETD2) OTQW463T SETD2_HUMAN Increases Expression [6]
Histone-lysine N-methyltransferase SETD5 (SETD5) OTRPAVEO SETD5_HUMAN Increases Expression [6]
Histone-lysine N-methyltransferase SMYD3 (SMYD3) OT9YR20G SMYD3_HUMAN Affects Expression [6]
N-lysine methyltransferase KMT5A (KMT5A) OTW2A5YY KMT5A_HUMAN Increases Expression [6]
Protein arginine N-methyltransferase 8 (PRMT8) OT3MRK62 ANM8_HUMAN Increases Expression [6]
NAD-dependent protein deacetylase sirtuin-3, mitochondrial (SIRT3) OTMEF544 SIR3_HUMAN Decreases Expression [16]
Protein arginine N-methyltransferase 7 (PRMT7) OTE73PO1 ANM7_HUMAN Increases Expression [6]
DNA (DNMT3B) OTZ0JCNP DNM3B_HUMAN Decreases Expression [6]
Lysine-specific demethylase 5B (KDM5B) OT5DL94T KDM5B_HUMAN Increases Expression [6]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Decreases Expression [6]
Aurora kinase C (AURKC) OTJMOW9V AURKC_HUMAN Increases Expression [6]
Histone deacetylase 5 (HDAC5) OTWG387P HDAC5_HUMAN Increases Expression [6]
Long-chain fatty acid transport protein 5 (SLC27A5) OT4OK511 S27A5_HUMAN Decreases Expression [25]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Affects Response To Substance [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 137 DOT(s)
Indication(s) of Carvedilol
Disease Entry ICD 11 Status REF
Chronic heart failure BD1Z Approved [2]
Congestive heart failure BD10 Approved [3]
Pulmonary hypertension BB01 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [4]
Carvedilol Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUAMN alpha-1 adrenergic receptor (ADRA1) TTDBOI7 ADA1A_HUMAN; ADA1B_HUMAN; ADA1D_HUMAN Inhibitor [30]
Adrenergic receptor Alpha-1 (ADRA1) TTG28O6 NOUNIPROTAC Antagonist [31]
HUMAN beta adrenergic receptor (BAR) TTJB8UY ADRB1_HUMAN; ADRB2_HUMAN; ADRB3_HUMAN Antagonist [4]
------------------------------------------------------------------------------------
Carvedilol Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [32]
------------------------------------------------------------------------------------
Carvedilol Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [33]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [34]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [35]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [36]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [37]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [38]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [35]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)
Carvedilol Interacts with 28 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Affects Glucuronidation [39]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [40]
Beta-1 adrenergic receptor (ADRB1) OTQBWN4U ADRB1_HUMAN Increases Activity [41]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [42]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Increases Phosphorylation [43]
Potassium channel subfamily K member 3 (KCNK3) OTWMAV6G KCNK3_HUMAN Decreases Activity [44]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Expression [45]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [46]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Expression [47]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Decreases Expression [48]
Vasopressin-neurophysin 2-copeptin (AVP) OTAVZ76K NEU2_HUMAN Decreases Expression [49]
Insulin (INS) OTZ85PDU INS_HUMAN Decreases Expression [50]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [51]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [52]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [53]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Increases Phosphorylation [42]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [47]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Affects Activity [54]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Decreases Expression [55]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Increases Expression [56]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Increases Expression [57]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [42]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [58]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Decreases Expression [55]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [52]
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Increases Activity [59]
Vascular endothelial growth factor receptor 2 (KDR) OT15797V VGFR2_HUMAN Increases ADR [60]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Increases ADR [60]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 DOT(s)

References

1 ClinicalTrials.gov (NCT04543643) Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis
2 Carvedilol FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 551).
4 Can beta-adrenergic blockers be used in the treatment of COVID-19 Med Hypotheses. 2020 May 5;142:109809.
5 Dual down-regulation of EGFR and ErbB2 by berberine contributes to suppression of migration and invasion of human ovarian cancer cells. Environ Toxicol. 2021 May;36(5):737-747. doi: 10.1002/tox.23076. Epub 2020 Dec 16.
6 Berberine acts as a putative epigenetic modulator by affecting the histone code. Toxicol In Vitro. 2016 Oct;36:10-17. doi: 10.1016/j.tiv.2016.06.004. Epub 2016 Jun 13.
7 Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/-catenin signaling pathway. Toxicol Lett. 2016 Jan 5;240(1):68-80. doi: 10.1016/j.toxlet.2015.10.007. Epub 2015 Oct 22.
8 Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103.
9 P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci. 2002 Dec;91(12):2614-21.
10 Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008 Feb;376(6):449-61.
11 Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: biphasic effect on CYP1A1. Biochem Pharmacol. 2005 Sep 15;70(6):925-36.
12 Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells. Chem Biol Interact. 2023 Apr 1;374:110408. doi: 10.1016/j.cbi.2023.110408. Epub 2023 Feb 21.
13 Multiple mechanisms of cell death induced by chelidonine in MCF-7 breast cancer cell line. Chem Biol Interact. 2014 Nov 5;223:141-9. doi: 10.1016/j.cbi.2014.09.013. Epub 2014 Sep 30.
14 Mechanism study of goldenseal-associated DNA damage. Toxicol Lett. 2013 Jul 31;221(1):64-72. doi: 10.1016/j.toxlet.2013.05.641. Epub 2013 Jun 5.
15 Studies on alkaloids binding to GC-rich human survivin promoter DNA using positive and negative ion electrospray ionization mass spectrometry. J Mass Spectrom. 2008 Mar;43(3):327-35. doi: 10.1002/jms.1320.
16 Concurrent acetylation of FoxO1/3a and p53 due to sirtuins inhibition elicit Bim/PUMA mediated mitochondrial dysfunction and apoptosis in berberine-treated HepG2 cells. Toxicol Appl Pharmacol. 2016 Jan 15;291:70-83. doi: 10.1016/j.taap.2015.12.006. Epub 2015 Dec 19.
17 Berbamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells. Cell Biol Toxicol. 2023 Aug;39(4):1297-1317. doi: 10.1007/s10565-022-09756-8. Epub 2022 Sep 7.
18 Identification of novel pregnane X receptor activators from traditional Chinese medicines. J Ethnopharmacol. 2011 Jun 14;136(1):137-43. doi: 10.1016/j.jep.2011.04.022. Epub 2011 Apr 16.
19 Cytotoxicity of berberine on human cervical carcinoma HeLa cells through mitochondria, death receptor and MAPK pathways, and in-silico drug-target prediction. Toxicol In Vitro. 2010 Sep;24(6):1482-90. doi: 10.1016/j.tiv.2010.07.017. Epub 2010 Jul 23.
20 Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth. Toxicol Appl Pharmacol. 2013 Nov 1;272(3):787-96. doi: 10.1016/j.taap.2013.08.008. Epub 2013 Aug 15.
21 Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer. 2008 Feb 25;8:58. doi: 10.1186/1471-2407-8-58.
22 Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006 Feb;5(2):296-308. doi: 10.1158/1535-7163.MCT-05-0448.
23 Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR- and subsequent expression of HGF in colons. Toxicol Appl Pharmacol. 2018 Mar 15;343:1-15. doi: 10.1016/j.taap.2018.02.001. Epub 2018 Feb 3.
24 Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2010 Apr;381(4):371-81. doi: 10.1007/s00210-010-0502-0. Epub 2010 Mar 13.
25 Activation of AMPK by berberine induces hepatic lipid accumulation by upregulation of fatty acid translocase CD36 in mice. Toxicol Appl Pharmacol. 2017 Feb 1;316:74-82. doi: 10.1016/j.taap.2016.12.019. Epub 2016 Dec 28.
26 Profiling the Tox21 Chemical Collection for Acetylcholinesterase Inhibition. Environ Health Perspect. 2021 Apr;129(4):47008. doi: 10.1289/EHP6993. Epub 2021 Apr 12.
27 Identification of Compounds That Inhibit Estrogen-Related Receptor Alpha Signaling Using High-Throughput Screening Assays. Molecules. 2019 Feb 27;24(5):841. doi: 10.3390/molecules24050841.
28 Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
29 Involvement of human hepatic UGT1A1, UGT2B4, and UGT2B7 in the glucuronidation of carvedilol. Drug Metab Dispos. 2004 Feb;32(2):235-9. doi: 10.1124/dmd.32.2.235.
30 Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol. 2003 Jan 15;41(2):340-5.
31 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
32 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
33 Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016 Jun 8;10:1909-16.
34 Pharmacokinetic interactions study between carvedilol and some antidepressants in rat liver microsomes - a comparative study. Med Pharm Rep. 2019 Apr;92(2):158-164.
35 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
36 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
37 In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997 Aug;25(8):970-7.
38 The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):79-86.
39 Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J Pharm Pharm Sci. 2006;9(1):101-12.
40 Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006 Jun;20(3):273-82. doi: 10.1111/j.1472-8206.2006.00408.x.
41 Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol. 2003 Jun;63(6):1312-21. doi: 10.1124/mol.63.6.1312.
42 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
43 Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14555-60.
44 Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels. Br J Pharmacol. 2011 Jul;163(5):1099-110. doi: 10.1111/j.1476-5381.2011.01319.x.
45 Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S124-9.
46 Renal and cardiac function during alpha1-beta-blockade in congestive heart failure. Scand J Clin Lab Invest. 2002;62(2):97-104. doi: 10.1080/003655102753611717.
47 [Arterial hypertension and oxidative stress induced by cyclosporin. Effect of carvedilol]. Ann Ital Med Int. 2001 Apr-Jun;16(2):101-5.
48 Effects of carvedilol on atrial natriuretic peptide, catecholamines, and hemodynamics in hypertension at rest and during exercise. J Cardiovasc Pharmacol. 1992;19 Suppl 1:S90-6. doi: 10.1097/00005344-199219001-00018.
49 Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press. 2002;11(6):377-84. doi: 10.1080/080370502321095357.
50 After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol. 2006 Feb;95(2):99-104. doi: 10.1007/s00392-006-0336-4. Epub 2006 Feb 6.
51 Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med. 2004 Apr 1;116(7):460-5. doi: 10.1016/j.amjmed.2003.10.029.
52 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
53 Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol. 1998 Jan;30(1):167-73. doi: 10.1006/jmcc.1997.0582.
54 Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). Pharmacol Res. 2006 Jul;54(1):57-64. doi: 10.1016/j.phrs.2006.02.006. Epub 2006 Feb 28.
55 Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J. 2009 Jun;73(6):1067-73. doi: 10.1253/circj.cj-08-1026. Epub 2009 Apr 14.
56 Reduced expression of endothelial connexins 43 and 37 in hypertensive rats is rectified after 7-day carvedilol treatment. Am J Hypertens. 2006 Feb;19(2):129-35. doi: 10.1016/j.amjhyper.2005.08.020.
57 Carvedilol modulates in-vitro granulocyte-macrophage colony-stimulating factor-induced interleukin-10 production in U937 cells and human monocytes. Immunol Invest. 2003 Feb;32(1-2):43-58. doi: 10.1081/imm-120019207.
58 Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res. 2001 Feb 1;49(2):361-70. doi: 10.1016/s0008-6363(00)00265-0.
59 Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003 May 20;107(19):2459-66. doi: 10.1161/01.CIR.0000068316.53218.49. Epub 2003 May 12.
60 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.